Skip to main content
OpenTrials
Completed

NCT Number: NCT00931775

Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder

The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Outpatients Service of Psychiatry Department. Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08025, Spain

About this study

Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram + placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected from a general hospital.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a depressive episode
  • HDRS score > 18
  • Written informed consent

Exclusion criteria

  • suicidal risk > 3
  • severe organic illness
  • other psychotropic drugs

Treatment and study plan

Pindolol

Drug

Pill orally administered. 15 mg/day t.i.d.

Primary outcomes

  1. Scores on Hamilton Depression Rating Scale

    Time frame: 8 time points through 6 weeks

Sponsors and collaborators

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Other

Registry information

Official study title

Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder

Acronym: CIT-PIN

Important dates

Study start
2002
Primary completion
2005
Study completion
2005
First posted
Jul 2, 2009
Registry last updated
Jul 2, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.